Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Astria Therapeutics Inc ATXS

Healthcare Biotechnology
Astria Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for allergic and immunological diseases. The Company's lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema (HAE), a rare, debilitating and potentially life-threatening disease. Its second program, STAR-0310, is a... see more

Recent & Breaking News (NDAQ:ATXS)

Investor Network: Catabasis Pharmaceuticals Inc to Host Earnings Call

Accesswire May 11, 2017

Technical Reports on Biotech Stocks -- Celsion, Incyte, ImmunoGen, and Catabasis Pharma

PR Newswire May 11, 2017

Catabasis Pharmaceuticals to Report First Quarter 2017 Financial Results and Recent Corporate Developments on Thursday, May 11

Business Wire April 27, 2017

Catabasis Pharmaceuticals Announces Favorable Results for Functional Assessments in the MoveDMD® Trial for Edasalonexent in Duchenne Muscular Dystrophy at the American Academy of Neurology 69th Annual Meeting

Business Wire April 25, 2017

Biotech Stocks on Investors' Radar -- Editas, Intra-Cellular, Aralez Pharma, and Catabasis Pharma

PR Newswire March 21, 2017

Catabasis Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Recent Corporate Highlights

Business Wire March 16, 2017

Catabasis Pharmaceuticals to Present at Oppenheimer’s 27th Annual Healthcare Conference

Business Wire March 15, 2017

12 Biggest Mid-Day Losers For Monday

Benzinga.com  March 13, 2017

Catabasis Pharmaceuticals to Present at the 2017 Muscular Dystrophy Association Scientific Conference

Business Wire March 13, 2017

15 Biggest Mid-Day Gainers For Friday

Benzinga.com  March 10, 2017

Catabasis Pharmaceuticals to Report Fourth Quarter and Full Year 2016 Financial Results and Recent Corporate Developments on Thursday, March 16

Business Wire March 2, 2017

Catabasis Pharmaceuticals to Present at Cowen and Company 37th Annual Health Care Conference

Business Wire March 1, 2017

Catabasis Pharmaceuticals Announces Promotion of Ted Hibben to Chief Business Officer

Business Wire February 17, 2017

Your Guide To 2017's Emerging Pharmaceuticals Catalysts

Benzinga.com  February 7, 2017

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Catabasis Pharmaceuticals, Inc.

Business Wire February 2, 2017

Mid-Morning Market Update: Markets Open Higher; Apple Tops Q1 Expectations

Benzinga.com  February 1, 2017

Catabasis Pharmaceuticals Announces Top-Line Results for Part B of the MoveDMD® Trial for Edasalonexent (CAT-1004) in Duchenne Muscular Dystrophy

Business Wire January 31, 2017

15 Biggest Mid-Day Gainers For Thursday

Benzinga.com  January 19, 2017

Mid-Morning Market Update: Markets Edge Higher; Netflix Earnings Top Expectations

Benzinga.com  January 19, 2017

Catabasis Pharmaceuticals Phase 1 Data on Edasalonexent (CAT-1004), a Potential Disease-Modifying Therapy Being Developed for Duchenne Muscular Dystrophy, Published in the Journal of Clinical Pharmacology

Business Wire January 19, 2017